Merck
Oncology/ Podcast/ Video/ Views & Analysis/ Views and analysis
Merck on trends in oncology: the pharmaphorum podcast
R&D/ Views & Analysis/ Views and analysis
Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4
mike.hammerton@pharmaphorum.com
Biogen, GSK, Merck, Q4 2021, quarterly results
0 Comment
Market Access/ Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis
A history of the pharmaceutical industry
Rebecca
A history of..., Aspirin, Bayer, Eli Lilly, GSK, History of the pharmaceutical industry, insulin, Merck, NHS, penicillin, Pfizer, Sandoz, Wyeth
0 Comment
Robin Walsh takes a look back at the origins of the industry in the 19th century and its ongoing evolution
Market Access/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis
MSD’s David Peacock on moving UK healthcare forward
mike.hammerton@pharmaphorum.com
coronavirus, COVID-19, Merck, Merck & Co, MSD, NHS, UK, UK Leaders
0 Comment
Deep Dive/ Patients/ Views & Analysis/ Views and analysis
True pharma-patient co-creation
mike.hammerton@pharmaphorum.com
co-creation, Deep Dive, Merck, MS patient group, Trishna Bharadia
0 Comment
SMC approves medicines for breast cancer, skin cancer, schizophrenia
George Underwood
Allergan, Eli Lilly, Keytruda, Lilly, Merck, Reagila, Scotland, SMC, Vernezio, Vernezios, Xonvea
0 Comment
Market Access/ News/ News/ Top stories
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer
George Underwood
AstraZeneca, breast cancer, Lynparza, Merck, MSD
0 Comment